Explore the vast range of titles available.

The synthesis is reported of some analogues of 3-deoxy-D-arabino-heptulosonic acid 7-phosphate (DAHP,3) an intermediate in the Shikimate pathway, and of some analogues of 3-deoxy- -D-arabino-heptulosonic acid 2,7-diphosphate (167), the intermediacy the existence of which is proposed in this thesis in a new alternative mechanism for the enzymic reaction catalysed by DAHP synthase. 2-Deoxy- - and - -D-arabino-hexopyranosyl-phosphonic acids (169) and (168) were synthesised in high yield from 2-deoxy-D-glucose (69). Acetylation of (69) in acetic anhydride and pyridine gave 1,3,4,6-tetra-O-acetyl-2-deoxy- , -D-arabino-hexopyranose (23 , ) which was then treated with trimethyl phosphite and trimethylsilyl triflate to give dimethyl (3,4,6-tri-O-acetyl-2-deoxy- - and - -D-arabino-hexopyranosyl)-phosphonates (180) and (181). These were deprotected with trimethylsilyl bromide followed by sodium methoxide in methanol to give the phosphonic acids (169) and (168). A stereospecific synthesis to give a protected form of (169) was also carried out. Tri-O-benzyl-D-glucal (80) was treated with hydrogen chloride gas in toluene followed by lithio tributylstannylate to give specifically tributyl (3,4,6-tri-O-benzyl-2-deoxy- -D-arabino-hexopyranosyl)stannane (204). Transmetallation with butyllithium followed by reaction with diethyl chlorophosphate then gave diethyl (3,4,6-tri-O-benzyl-2-deoxy- -D-arabino-hexopyranosyl)-phosphonate (208). As an alternative 3,4,6-tri-O-t-butyldiphenylsilyl-D-glucal (228) was synthesised from D-glucal (176) and was treated with t-butyllithium followed by diethyl chlorophosphate to give diethyl (tri-O-t-butyldiphenylsilyl-2-deoxy-D-arabino-hex-1-enopyranosyl)-phosphonate (229). An attempt to hydrogenate this specifically to give a protected -phosphonate was unsuccessful. (DX179064)

Work now invariably requires a continual focus on learning: to improve productivity, to enhance the flexibility of employees and to develop and transform organizations. This volume brings together leading experts from the United States, Britain, Australia and New Zealand to critically evaluate the current debates on workplace learning and to propose directions for future developments in both research and practice. Topics covered include: expectations about learning at work into the twenty-first century; learning theories, practice and performance implications; the relationship between workplace learning and other forms of life-long education; international developments in competency-based approaches to learning and assessment; the influence of language, power, culture and gender upon the 'construction' of learning. Understanding Learning at Work will be an invaluable resource for students and practitioners interested in training, human resource development (HRD), continuing and adult education and provides a state-of-the-art summary of the issues and opportunities involved.

ObjectiveManagement of acute severe UC (ASUC) during the novel COVID-19 pandemic presents significant dilemmas. We aimed to provide COVID-19-specific guidance using current British Society of Gastroenterology (BSG) guidelines as a reference point.DesignWe convened a RAND appropriateness panel comprising 14 gastroenterologists and an IBD nurse consultant supplemented by surgical and COVID-19 experts. Panellists rated the appropriateness of interventions for ASUC in the context of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Median scores and disagreement index (DI) were calculated. Results were discussed at a moderated meeting prior to a second survey.ResultsPanellists recommended that patients with ASUC should be isolated throughout their hospital stay and should have a SARS-CoV-2 swab performed on admission. Patients with a positive swab should be discussed with COVID-19 specialists. As per BSG guidance, intravenous hydrocortisone was considered appropriate as initial management; only in patients with COVID-19 pneumonia was its use deemed uncertain. In patients requiring rescue therapy, infliximab with continuing steroids was recommended. Delaying colectomy because of COVID-19 was deemed inappropriate. Steroid tapering as per BSG guidance was deemed appropriate for all patients apart from those with COVID-19 pneumonia in whom a 4–6 week taper was preferred. Post-ASUC maintenance therapy was dependent on SARS-CoV-2 status but, in general, biologics were more likely to be deemed appropriate than azathioprine or tofacitinib. Panellists deemed prophylactic anticoagulation postdischarge to be appropriate in patients with a positive SARS-CoV-2 swab.ConclusionWe have suggested COVID-19-specific adaptations to the BSG ASUC guideline using a RAND panel.

Background Accurately recognizing that a person may be dying is central to improving their experience of care at the end-of-life. However, predicting dying is frequently inaccurate and often occurs only hours or a few days before death. Methods We performed urinary metabolomics analysis on patients with lung cancer to create a metabolite model to predict dying over the last 30 days of life. Results Here we show a model, using only 7 metabolites, has excellent accuracy in the Training cohort n  = 112 (AUC = 0·85, 0·85, 0·88 and 0·86 on days 5, 10, 20 and 30) and Validation cohort n  = 49 (AUC = 0·86, 0·83, 0·90, 0·86 on days 5, 10, 20 and 30). These results are more accurate than existing validated prognostic tools, and uniquely give accurate predictions over a range of time points in the last 30 days of life. Additionally, we present changes in 125 metabolites during the final four weeks of life, with the majority exhibiting statistically significant changes within the last week before death. Conclusions These metabolites identified offer insights into previously undocumented pathways involved in or affected by the dying process. They not only imply cancer’s influence on the body but also illustrate the dying process. Given the similar dying trajectory observed in individuals with cancer, our findings likely apply to other cancer types. Prognostic tests, based on the metabolites we identified, could aid clinicians in the early recognition of people who may be dying and thereby influence clinical practice and improve the care of dying patients. Coyle et al. utilize urinary metabolomics analysis to predict dying over the last 30 days of life in patients with lung cancer and provide insights into the dying process. The metabolite model provides prognostic information at the end of life allowing for the early recognition of people who may be dying and improve the care of these patients. Plain Language Summary Recognizing when someone is nearing the end of life is important for providing better care, but it is often hard to predict accurately. In our study, we analyzed urine samples from lung cancer patients to develop a method that can predict when a person is in their last 30 days of life. We identified 7 key chemicals in the urine that helped us predict death with high accuracy. This method worked better than current tools and provided reliable predictions throughout the last month of life. We also found changes in many other chemicals in the final weeks. These findings could help doctors identify when a patient is dying earlier, leading to better care at the end of life.